Nasdaq: ADAP

Adaptimmune

Adaptimmune is a clinical stage biotechnology company focused on the development of T cell therapies to treat cancer. The company aims to utilize the body’s own immune system to target and destroy cancer by using engineered, increased affinity T cell receptors (TCRs) as a means of strengthening natural patient T cell responses. It has one clinical stage asset and two preclinical stage assets all for the treatment of various forms of cancer. Its lead program is an engineered higher-affinity TCR targeting the NY-ESO-1 cancer testis antigen. ADAP is developing the NY-ESO TCR therapeutic candidate for treatment of patients with solid tumors and hematological malignancies including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer and esophageal cancer.